



## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

**Common Name:** Daptomycin for Injection  
**Synonyms:** NA  
**Product use:** Antibacterial agent  
**Manufacturing site:** Biological E. Limited,  
Plot No: 4, Sy. No 542/P, Biotech Park, Phase-II,  
Kolthur Village-500078,  
Shameerpet Mandal,  
Medchal District, Telangana state, India.

#### **Manufacturer Contact Details:**

Telephone (Technical Contact): + 91-40 30128000, 71216000  
Telephone (Business Contact): + 91-40 30549503  
Fax No.: + 91-40 27616715  
E-mail Address: info@biologicale.com

### 2. HAZARDS IDENTIFICATION

**Classification of the Substance or Mixture GHS - Classification Specific target organ systemic toxicity (repeated exposure):** Category 2

**US OSHA Specific - Classification Physical Hazard:** Combustible Dust

**Label Elements Signal Word: Warning Hazard Statements:**

H373 - May cause damage to organs through prolonged or repeated exposure May form combustible dust concentrations in air

**Precautionary Statements:**

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P314 - Get medical attention/advice if you feel unwell

P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards An Occupational Exposure Value has been established for this substance ( see Section 8 ).



## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

### **Note:**

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### **3. COMPOSITION/INFORMATION ON INGREDIENTS**

#### **Component(s):**

<b>Chemical name</b>	<b>CAS-No.</b>	<b>GHS Classification</b>	<b>Concentration</b>
Sodium hydroxide	1310-73-2	Skin Corr.1A (H314)	To adjust pH
Daptomycin	103060-53-3	STOT SE 2 (H373)	100 %

### **4. FIRST AID MEASURES**

#### **Description of First Aid Measures**

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### **Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

#### **Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:** None



## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

---

### 5. FIRE FIGHTING MEASURES

**Extinguishing media:** Use carbon dioxide, dry chemical, or water spray.

#### **Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Advice for Fire-Fighters:** During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### **Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### **Methods and Material for Containment and Cleaning Up**

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

#### **Additional Consideration for Large Spills:**

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

#### **Precautions for Safe Handling**

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water



## BIOLOGICAL E. LIMITED

### *SDS: Safety Data Sheet*

and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### **Conditions for Safe Storage, Including any Incompatibilities**

**Storage Conditions:** Store as directed by product packaging. Specific end use(s):  
Pharmaceutical drug product

## **8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### **Control Parameters**

#### **Sodium hydroxide**

**ACGIH Ceiling Threshold Limit:** 2 mg/m<sup>3</sup>

**Australia PEAK:** 2 mg/m<sup>3</sup>

**Austria OEL – MAKs:** 2 mg/m<sup>3</sup>

**Bulgaria OEL – TWA:** 2.0 mg/m<sup>3</sup>

**Czech Republic OEL – TWA:** 1 mg/m<sup>3</sup>

**Estonia OEL – TWA:** 1 mg/m<sup>3</sup>

**France OEL – TWA:** 2 mg/m<sup>3</sup>

**Greece OEL – TWA:** 2 mg/m<sup>3</sup>

**Hungary OEL – TWA:** 2 mg/m<sup>3</sup>

**Japan - OELs – Ceilings:** 2 mg/m<sup>3</sup>

**Latvia OEL – TWA:** 0.5 mg/m<sup>3</sup>

**OSHA - Final PELs - TWAs:** 2 mg/m<sup>3</sup>

**Poland OEL – TWA:** 0.5 mg/m<sup>3</sup>

**Slovakia OEL – TWA:** 2 mg/m<sup>3</sup>

**Slovenia OEL – TWA:** 2 mg/m<sup>3</sup>

**Sweden OEL – TWAs:** 1 mg/m<sup>3</sup>

**Switzerland OEL -TWAs:** 2 mg/m<sup>3</sup>

#### **Daptomycin**

**Occupational Exposure Band (OEB):** OEB 2 (control exposure to the range of 100ug/m<sup>3</sup> to < 1000ug/m<sup>3</sup>)

#### **Exposure Controls**



## BIOLOGICAL E. LIMITED

### *SDS: Safety Data Sheet*

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:**

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

**Hands:** Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

**Eyes:** Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

**Respiratory protection:** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

## 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Appearance</b>	: Pale yellow to light brown, lyophilized cake or powder
<b>Odor</b>	: Odorless.





## BIOLOGICAL E. LIMITED

### *SDS: Safety Data Sheet*

---

<b>Solubility</b>	: Freely soluble in water, the solubility is 1 g/mL at 25 <sup>0</sup> C; Freely soluble in 0.1 mol/L NaOH; Insoluble in isopropanol, ethyl acetate, chloroform and acetonitrile
<b>Density</b>	: No information found.
<b>pH</b>	: 4.5 – 5.0

**Melting/Freezing Point (°C):** 215

**Boiling Point (°C):** No data available.

**Partition Coefficient:** (Method, pH, Endpoint, Value)

**Sodium hydroxide:** No data available

**Daptomycin:** No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

**Polymerization:** Will not occur

## 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable if stored in accordance with information listed on the product insert.

**Possibility of hazardous reactions:**

**Oxidizing Properties:** No data available



## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects Short Term:

Accidental ingestion may cause effects similar to those seen in clinical use.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include headache, allergic skin rash, liver effects, effects on musculoskeletal system, muscle pain, muscle weakness neuromuscular effects. Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Sodium hydroxide

Mouse IP LD50 40 mg/kg

##### Daptomycin

Rat Oral Minimum Lethal Dose > 2000 mg/kg

Rat Dermal Minimum Lethal Dose > 200mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

##### Daptomycin

Skin Irritation Rabbit Slight

Eye Irritation Rabbit Slight



## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

---

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Daptomycin

1 Month(s)	Rat	Intravenous	10 mg/kg/day	LOAEL	Skeletal muscle, Kidney
3 Month(s)	Rat	Intravenous	1 mg/kg/day	LOAEL	Skeletal muscle, Kidney
6 Month(s)	Rat	Intravenous	2 mg/kg/day	LOAEL	Kidney, Skeletal muscle, Bone Marrow
1 Month(s)	Dog	Intravenous	10 mg/kg/day	LOAEL	Bone Marrow, Skeletal muscle, Peripheral nervous system

### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Daptomycin

Reproductive & Fertility	Rat	Intravenous	150 mg/kg/day	NOAEL	Negative
Embryo / Fetal Development	Rat	Intravenous	75 mg/kg/day	NOAEL	Negative, Not Teratogenic
Embryo / Fetal Development	Rabbit	Intravenous	75 mg/kg/day	NOAEL	Negative, Not Teratogenic

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Daptomycin

Bacterial Mutagenicity (Ames)	Salmonella, E. coli	Negative
Mammalian Cell Mutagenicity	Not specified	Negative
Chromosome Aberration	Chinese Hamster Ovary (CHO) cells	Negative
In Vivo Micronucleus	Mouse	Negative
In Vivo Sister Chromatid Exchange	Hamster	Negative

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.





## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

---

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated.

**Toxicity:**

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

**The following refers to all modes of transportation unless specified below.**

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**Sodium hydroxide**

**CERCLA/SARA 313 Emission reporting:** Not Listed

**CERCLA/SARA Hazardous Substances:** 1000lb

**and their Reportable Quantities:** 454 kg

**California Proposition 65:** Not Listed

**Inventory - United States TSCA - Sect. 8(b):** Present



## BIOLOGICAL E. LIMITED

*SDS: Safety Data Sheet*

---

**Australia (AICS):** Present

**Standard for the Uniform Scheduling:** Schedule 5

**for Drugs and Poisons:** Schedule 6

**EU EINECS/ELINCS List:** 215-185-5

### **Daptomycin**

**CERCLA/SARA 313 Emission reporting:** Not Listed

**California Proposition 65:** Not Listed

**Standard for the Uniform Scheduling for Drugs and Poisons:** Schedule 4

**EU EINECS/ELINCS List:** Not Listed

## **16. OTHER INFORMATION**

**Disclaimer:** Biological E. Limited provides the information without warranty and contained herein in good faith but makes no representation as to its comprehensiveness or accuracy. This document is intended only as a guide to the appropriate precautionary handling of the material by a properly trained person using this product individuals receiving the information must exercise their independent judgment in determining its appropriateness for a particular purpose. Biological E. Limited will not be responsible for damages resulting from use or reliance upon information.

*And*  
27/06/19